- Home
- COHR vs GMAB Comparison
COHR vs GMAB Comparison
Compare COHR & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COHR
- GMAB
- Stock Information
- Founded
- COHR 1971
- GMAB 1999
- Country
- COHR United States
- GMAB Denmark
- Employees
- COHR N/A
- GMAB N/A
- Industry
- COHR Electronic Components
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- COHR Technology
- GMAB Health Care
- Exchange
- COHR Nasdaq
- GMAB Nasdaq
- Market Cap
- COHR 14.5B
- GMAB 13.2B
- IPO Year
- COHR 1987
- GMAB N/A
- Fundamental
- Price
- COHR $89.87
- GMAB $24.65
- Analyst Decision
- COHR Strong Buy
- GMAB Buy
- Analyst Count
- COHR 16
- GMAB 6
- Target Price
- COHR $109.40
- GMAB $37.60
- AVG Volume (30 Days)
- COHR 5.4M
- GMAB 1.2M
- Earning Date
- COHR 08-13-2025
- GMAB 08-07-2025
- Dividend Yield
- COHR N/A
- GMAB N/A
- EPS Growth
- COHR N/A
- GMAB 77.72
- EPS
- COHR N/A
- GMAB 21.62
- Revenue
- COHR $5,810,115,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- COHR $11.70
- GMAB $21.64
- Revenue Next Year
- COHR $5.99
- GMAB $15.57
- P/E Ratio
- COHR N/A
- GMAB $11.06
- Revenue Growth
- COHR 23.42
- GMAB 32.97
- 52 Week Low
- COHR $45.58
- GMAB $17.24
- 52 Week High
- COHR $123.25
- GMAB $27.94
- Technical
- Relative Strength Index (RSI)
- COHR 40.25
- GMAB 67.82
- Support Level
- COHR $84.35
- GMAB $21.00
- Resistance Level
- COHR $95.37
- GMAB $22.90
- Average True Range (ATR)
- COHR 4.43
- GMAB 0.43
- MACD
- COHR -3.09
- GMAB 0.24
- Stochastic Oscillator
- COHR 14.19
- GMAB 95.31
About COHR Coherent Corp.
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.